Related Experiment Video
Updated: Sep 10, 2025

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
Published on: June 20, 2025
Alkaloids as Emerging Therapeutics against Pulmonary Fibrosis: Classification, Mechanisms, and Translational
Yafang Wang1, Chunlei Hua2, Henghui Zhang3
1Department of Rheumatology and Immunology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, China.
None:
Pulmonary fibrosis (PF) is a chronic and progressive lung disease characterized by an unclear etiology and poor prognosis. Currently, the therapeutic drugs available for PF are limited and insufficient to meet the clinical demands. In recent years, the anti-PF potential of natural products has garnered increasing attention, with alkaloids showing particularly promising prospects. Alkaloids can intervene PF through multiple signaling pathways. Alkaloids exert anti-inflammatory, antioxidant, and antiapoptotic effects, which contribute to the inhibition of extracellular matrix (ECM) deposition, the protection of alveolar epithelial cells, and the suppression of lung fibroblast activation and proliferation involved in PF. However, a comprehensive and systematic synthesis of the existing research remains lacking. This review emphasizes the summary of the mechanisms by which alkaloids prevent and treat PF, including experimental research methodologies and clinical research findings. In addition, it highlights the existing challenges and outlines potential directions for future research, with the goal of providing new insights into the development of novel therapeutic agents for PF prevention and treatment.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drug Discovery: Overview
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

